Kissing-Watchman technique applied in single-lobulated left atrial appendage anatomy with giant ostia

Authors: Linying Xia, Yi Liu, Ling Tao

DOI: 10.5603/CJ.a2019.0070

Article type: Technology notes

Submitted: 2019-04-03

Accepted: 2019-07-04

Published online: 2019-07-08

This article has been peer reviewed and published immediately upon acceptance. It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Cardiology Journal" are listed in PubMed.
TECHNICAL NOTE

Kissing-Watchman technique applied in single-lobulated left atrial appendage anatomy with giant ostia

Short Title: Kissing-WM in single-lobulated-giant LAA

Lining Xia*, Yi Liu*, Ling Tao

Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Shaanxi, China

Address for correspondence: Ling Tao, MD, PhD, Professor and Chief, Department of Cardiology, Xijing Hospital, Fourth Military Medical University, 15 Changle West Road, Xi’an 710032 China., tel: 86-29-8477-5183, fax: 86-29-8321-1024, e-mail: lingtao@fmmu.edu.cn

*The first two authors contributed equally to this work.

Abstract

Background: The Watchman device is the predominant occluder in China. However, the large left atrial appendage (LAA) ostium cannot be completely closed using a single Watchman device with the current sizes available. The aim of this pilot study was to evaluate the safety of the kissing-Watchman technique in single-lobulated LAA with large-ostia anatomy.

Methods: Three out of 100 consecutive patients, who underwent kissing-Watchman occlusion under the guidance of transesophageal echocardiography (TOE), were included in this study.

Results: All procedures were successful, with no severe complications. TOE performed three months after the procedure showed adequate LAA sealing, without thrombus formation on the devices. The 12-month follow-up was uneventful.
Conclusions: When necessary, the implantation of a kissing-device to achieve complete LAA occlusion in patients with single-lobulated left atrial appendage and giant ostia anatomy is safe and leads to favorable results during follow-up. Potentially, this technical innovation may widen Watchman indications in single-lobulated left atrial appendage with giant ostia anatomy.

Key words: Watchman; kissing, left atrial appendage

The only commercially available device in the documented institution is the Watchman (Boston Scientific, Marlborough, MA, USA) occluder which is the predominant occluder in China. The single device approach may not always fit the great anatomic variability of the left atrial appendage (LAA). Adequate closure may require more than a single device. The commercially available Watchman device only fits LAAs with a maximum diameter of 30 mm [1–3]. In patients with bilobulated LAA, the one-stop implantation of double Watchman is feasible as reported by a previous study [4]. However, it is unknown whether this approach is feasible in the setting of a single-lobulated LAA with a giant ostium (>30 mm). Reported herein, is a consecutive case series of patients in whom kissing-Watchman was performed to achieve adequate closure of the single-lobulated LAA with large-ostium.

Three out of 100 consecutive patients underwent kissing-Watchman occlusion under the guidance of transesophageal echocardiography (TEE). This experimental procedure was preceded with the patient’s acceptance. Before intervention, TEE was performed to exclude thrombi in the LAA. The procedures were performed via femoral access under general anesthesia, and were controlled by the angiography and TEE. At the beginning of the intervention, 5000 units of heparin were given. After transseptal passage, TEE measurement of the LAA diameter at the intended implantation site was performed at four different angles. According to the three cases, the maximal LAA ostia diameters were 35, 36, and 33 mm, respectively. The first occluder was deemed to cover half of the estimated LAA orifice area (d1 =
LAAmax/√2). Additionally, the size of the first Watchman device should be greater than or equal to the size of the second device. The second occluder was chosen based on residual space. The first Watchman device was pre-released and held still at the intended implantation site (Fig. 1A). After another transseptal puncture via the same femoral site, the pigtail catheter with the second access sheath was delivered carefully to the uncovered space parallel to the first access sheath and contrast injection was made (Fig. 1B). Excessive adjustment was avoided in order to minimize the sheath-sheath interplay. The second Watchman device was chosen according to the residual stump and was carefully placed next to the first device in a kissing fashion. Two Watchman devices were deployed adjacently. Therefore, complete LAA closure was achieved. Fluoroscopy and TEE were used to confirm the position, size and seal of the kissing device. The tug-test was performed on the two devices by pulling the parallel the parallel and deliver the system simultaneously to avoid dislocation (Fig. 1C). The two devices were released respectively after the PASS criteria had been met (Fig. 1D). The final diameters of each kissing-Watchman deployed were measured by TEE and the maximum device compression ratio of the kissing-Watchman LAA closure should be larger than a single device LAA closure technique (the upper limit was not limited to 30%). This higher compression ratio contributed to a more radical deformation of the kissing-device on the mutual compression side reducing the possibility of inter-device residual flow. Larger endotheliazation area of the kissing device contributes to prolongation of antithrombotic/antiplatelet therapy (3-month antithrombotic therapy or 12-month antiplatelet therapy). TEE 3-month and 12-month was scheduled after kissing-Watchman implantation.

The first patient was a 70-year-old male with a CHA2DS2-VASc score of 3. He was referred for LAA closure due to gastrointestinal bleeding on Warfarin. TEE showed a single lobe LAA with a maximum LAA ostium of 35 mm (Suppl. Fig. 1A). In a single intervention, the giant LAA was partially closed by the implantation of a 27 mm Watchman, and the remaining ostium with a diameter of 12.3 mm was closed by implantation of another 21 mm Watchman (Suppl. Fig. 1B). TEE showed that the maximum device compression ratio of the kissing-Watchman LAA closure was 19%
and a complete LAA closure was achieved (Suppl. Fig. 1C, D). The patient was placed on full dose rivaroxaban for three months after the intervention and dual antiplatelet therapy daily afterwards. A TEE performed three months later showed good position of both devices, with a newly formed gap of 4.6 mm (Suppl. Fig. 1E). The patient remained asymptomatic. Twelve months after the intervention, TEE confirmed an adequate occlusion with a remarkably shrinking peri-device flow of 1.8 mm and no device related thrombus was identified (Suppl. Fig. 1F).

The second patient was a 55-year-old male patient who underwent closure of a giant single-lobulated LAA due to paroxysmal atrial fibrillation, CHA\textsubscript{2}DS\textsubscript{2}-VASc score of 4, and recurrent stroke under Warfarin. TEE showed a single lobe LAA with a maximum LAA ostium of 36 mm without a ridge-like pectinate muscle inside (Suppl. Fig. 2A). Knowing that two devices would be necessary, the giant LAA was partially closed by implantation of a 27 mm Watchman leaving a 24 mm opening stump (Suppl. Fig. 2B). Therefore, complete LAA closure was achieved by the subsequent implantation with an additional 27 mm Watchman (Suppl. Fig. 2C, D). The maximum device compression ratio of the kissing-Watchman system was 33.3%. The patient was discharged on 110 mg dabigatran bid for the first 3 months post-operation and dual antiplatelet therapy for the following 8 months. TEE 3-month and 1-year post-operation follow-up showed adequate LAA sealing, with a persistent residual flow of 1.6 mm in the LAA and no device related thrombus was identified (Suppl. Fig. 2E, F). One year after the intervention the patient remained free of symptoms on acetylsalicylic acid 100 mg daily indefinitely.

The third patient was a 78-year-old man with a previous stroke, a CHA\textsubscript{2}DS\textsubscript{2}-VASc score of 4, and chronic kidney disease precluding the use of Warfarin. TEE demonstrated a large single-lobulated LAA with a 33 mm ostium and many pectinate muscles deep inside (Suppl. Fig. 3A). Knowing that two devices would be necessary, 27 mm Watchman was placed at the entrance of the LAA. It partially occluded LAA with a 14 mm residual stump uncovered (Suppl. Fig. 3B). A subsequent implantation with an additional 21 mm Watchman was achieved to completely occlude this large LAA (Suppl. Fig. 3C–E). The maximum compression
ratio of the kissing-Watchman system was 28.6%. The patient was prescribed with dual antiplatelet daily for the following 12 months, post-implantation. TEE performed after 3 months showed good position of both devices, with no evidence of residual shunt (Suppl. Fig. 3F). The clinical follow-up was uneventful.

There is a myriad of variations of LAA anatomy in terms of number of lobes and size of orifices [5]. One restriction inherent in single-device LAA occlusion technique concerns the maximum LAA body size suitable for intervention. Though there are larger sizes in other devices nowadays, the largest commercially available Watchman device only fits LAA with a maximum diameter of 30 mm [1]. Therefore, for an LAA ostium > 31 mm, it is difficult to obtain complete closure with a single Watchman device. The implantation of double Watchman is recommended in bilobulated LAA anatomy [1–3]. It remains controversial whether kissing-device, deployed adjacently in the same lobe is safe. Some scientists argue that there are several potential procedural risks [4]: 1) A severe residual flow between devices can exist; 2) the fixation barbs may injure the permeable polyester polyethylene (PET) membrane of the first device while deploying the second device; 3) due to the long-term mechanical interaction, device embolization may occur. In a considered opinion, to avoid potential peri-operative complications, it is important to: 1) select the kissing-device of identical or similar size to facilitate closer contact between the two devices minimizing residual shunting between them; 2) a more liberal oversizing technique (higher compression ratio) helps to minimize inter-device flow and also contributes to a greater radial force for stability; 3) deformation of the kissing-device on the mutual compression side contributes to minimizing potential leak between the kissing-devices.

No device dislocation, severe residual flow (> 5 mm) or device related thrombosis was observed, aside from the minor (< 3 mm) peri-device leakage identified at both 3-month and 12-month TEE follow-up. It was reported that, in patients who had undergone single Watchman LAA closure, an intraprocedural gap could persist, and could close or close and reopen during the follow-up period [6]. Therefore, in patients who underwent kissing-Watchman implantation, a mild
peri-device leak during TEE follow-up may not be related to interaction between the devices. Additionally, a peri-device gap with mild blood leak may not affect the stability of the Watchman device inside LAA, as evidenced by the fact that no device dislodgement occurred in patients of the present study.

Due to individual anatomic variations, a single Watchman device may not always adequately seal the LAA. In these cases, implantation of kissing-Watchman in single-lobulated LAA with giant ostia may afford a good anatomical result. Larger cohorts are needed to corroborate the safety and efficacy of this technical innovation.

Conflict of interest: None declared

References


Figure 1. Diagram of kissing-Watchman technique; A. The first device is pre-released
and held still at the intended implantation site, leaving a residual stump uncovered; B. The second access sheath is delivered to the uncovered space parallel to the first access sheath; C. The tug test is performed on the kissing-devices simultaneously; D. The two devices are released after the PASS criteria have been met.
The first device is pre-released and held still at the intended implantation site leaving a residual stump uncovered.

The second access sheath is delivered to the uncovered space parallel to the first access sheath.

The tug test is performed on the kissing-devices simultaneously.

The two devices are released after the PASS criteria have been met.

Tug simultaneously.